Is anyone following the Epogen issues - media attention - Amgen - guidelines - controversy with FDA warning being sent out to providers to stay within the designated numbers ... Wondering how many patients have hgb over 12.5? Epogen, for example, provides about 22% revenue for FMC but Davita is on the carpet with the government AGAIN for their Epogen usage.
Ofcourse, bottom line is that the patient suffers. Woudl like to know nurses experiences in addressing these issues with their medical directors - i.e. hgb is high, continuing to give Epo (per Dr.)?